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for Essential Health Benefits (EHBs). Primary discussions with US private payers 
and ex-CMS policy experts were conducted to understand key issues for medical 
products. RESULTS: The ACA has introduced major changes for product pricing, 
deductible, coverage and uptake. For pricing, major changes are a 50% discount for 
Part D population and an increased rebate of 23.1% for the Medicaid population. 
For deductibles, the patient costs are capped at $12,700. For uptake, an additional 
population is eligible based on expanded access to 30 million uninsured Americans, 
with more than half of them being under the age of 35 years (~59%). For access, 
the 2014 definition of Essential Drug Benefits is likely to either expand or reduce 
coverage depending upon the state and class of drugs. For example, for NSAIDs 
in CA only 20 drugs are covered, while in NY, 40 drugs are covered. During 2012-
2014 Accountable Care Organizations (ACOs) have increased to ~600 organizations 
covering ~18 million lives, which has created a new stakeholder of an integrated 
provider-payer partnership. CONCLUSIONS: ACA has introduced major changes 
which will have a significant impact on converge, pricing and access of pharma-
ceutical and device products.
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OBJECTIVES: Determine if EU pricing and reimbursement (P&R) bodies have revised 
their P&R approval processes for biosimilar medicines to enable faster access and 
optimize the potential healthcare savings. This study analyzed the biosimilar P&R 
procedures across Europe to determine how these differed to the standard and 
generic P&R approval processes. METHODS: OECD pharmaceutical spend data 
across Europe was utilized to identify the European countries that account for 90% 
of EU pharmaceutical spend. The official P&R websites for these 12 countries (France, 
Germany, Italy, Spain, UK, Austria, Poland, Belgium, Netherlands, Sweden, Greece, 
and Switzerland) were identified and analyzed to determine if biosimilar P&R pro-
cess followed the standard, generic or a specific biosimilar P&R approval process. If 
no biosimilar P&R documents were identified, the inference was that they follow the 
standard P&R approval process. RESULTS: Of the 12 countries reviewed, 8 require 
biosimilars to undergo the full standard P&R process, often requiring submission 
of comparative clinical data and development of health economic and/or budget 
impact models. In addition, Switzerland and Spain mandated an additional bio-
similar price discount be applied. 3 markets applied the generic approval process 
to biosimilars, enabling faster access to market. Italy was the only country having a 
specific, abridged biosimilar P&R pathway, where faster access to market is achieved 
if a pre-specified biosimilar price discount, dependent on the sales of the reference 
product, is applied. CONCLUSIONS: In the majority of European countries biosimi-
lars, unlike generics, are still required to undergo a comprehensive standard P&R 
process. Such processes are time consuming, resource intensive and costly for both 
the manufacturers and P&R bodies. The implication is that European payers have 
yet to consider biosimilars to be clinically comparable to their reference products 
or to fully recognise the potential healthcare savings from having an expedited 
biosimilar P&R approval process.
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OBJECTIVES: World Health Organisation (WHO)-CHOICE promotes a threshold 
defined as three times (3x) gross domestic product (GDP) per capita as a guide to deter-
mining cost-effectiveness of health interventions. This analysis sought to evaluate 
the stability of the 3x threshold over time for different countries and the implications 
of this for frequency of requirements to update the threshold value. METHODS: GDP 
per capita data from 2000 to 2014 were taken from the International Monetary Fund 
dataset and used to calculate 3x thresholds for a range of countries considered to be 
representative of different sizes of economies and levels of economic development. 
Proportional changes in the 3x threshold across the entire period and on a year-by-
year basis were analyzed, and time to doubling (and increase by other magnitudes) 
of the initial cost-effectiveness threshold was explored. RESULTS: The 3x threshold 
has increased over the period 2000 to 2014 for 99% of all countries analyzed. The 
average proportional increase in the 3x threshold over this period varied consid-
erably by country, with Belarus having the highest proportional increase over the 
entire time period (94 times). Time to doubling of the 3x threshold was highly variable 
(range 2.1 – 450 years [median 9.1 years]) and was as low as 2 – 3 years for a number 
of countries. High levels of variability were observed between countries within the 
same WHO country groupings. CONCLUSIONS: The results suggest that considerable 
proportional changes to the value of the 3x threshold are observed for a number of 
countries over the short-term. For some countries, the cost-effectiveness threshold 
would be expected to increase dramatically even over a yearly timescale. This research 
highlights the need for countries looking to adopt this threshold to carefully consider 
requirements for updating the threshold and for managing the impact of this, for 
instance in relation to incentives for delayed pharmaceutical entry.
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OBJECTIVES: The objectives of this study were to examine the potential barriers 
to new drug accessibility by exploring factors associated with the marketing lag 
and reimbursement lag, and comparing Taiwan’s approval lag with selected coun-
tries. METHODS: This study focused on new drugs reviewed by Taiwan’s NHI Drug 
Review Committee (DRC) from March, 2001 to December, 2012. Linear regression 
was adopted to estimate factors associated with the marketing lag. A two-part 
drugs at BRL 61 million. CONCLUSIONS: The responsible use of OTC medicines 
can reduce up to 21% the volume of emergency attendances, and for every BRL 1 
spent with OTC drugs is equivalent to an economy of BRL 7 in the public health 
system by reducing emergency visits and improductible days. The self-care, if done 
properly, can be an important factor in the improvement of public health, increas-
ing productivity and reducing costs, in addition to providing more time for health 
professionals in the care of more complex cases. Notwithstanding the expansion 
of OTC drugs usage should be conducted responsibly with quality products and 
effective pharmaceutical care.
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BACKGROUND: Prescription medication adherence is a known health related bar-
rier for elderly patients, leading to insufficient disease control and negative health 
outcomes. Many barriers to prescription adherence have been identified in the litera-
ture, but it is unclear what barriers physicians feel most strongly inhibit adherence 
among patients enrolled in Medicare Advantage Part D (MAPD) plans. OBJECTIVES: 
To identify physician perceived barriers to medication adherence among MAPD 
patients. METHODS: A survey was developed and administered to primary care 
physicians (PCPs) contracted within a MAPD plan in Texas. Surveys were distributed 
during an all-PCP quarterly meeting to increase completion and return rates, and 
were collected prior to the meeting’s conclusion. A free response section was utilized 
for PCPs to indicate up to 3 of the top barriers to medication adherence that they feel 
impact their MAPD patients. Responses were categorized into 8 distinct groups (cost, 
side effects, formulary, lack of patient understanding, forgetfulness, transportation, 
dosage changes, and other). The “other” category encompassed cultural issues, lan-
guage barriers, obtaining drugs out of the country or not using an insurance card, 
and problems at the pharmacy. RESULTS: A total of 210 PCPs (68%) across Texas 
completed and returned the survey. Cost was by far the most commonly identified 
barrier, reported by 77% of respondents. Patient understanding was also a big concern, 
identified by 53% of PCPs. Only 18% of PCPs indicated side effects (actual or potential) 
as a top barrier. Forgetfulness was cited by 22% of PCPs and transportation by 14%. 
Twenty percent of PCP responses fell within the “other” category defined above, while 
formulary (10%) and dosage change (2%) were the least frequently mentioned bar-
riers. CONCLUSIONS: MAPD PCPs most frequently cite financial issues and lack of 
patient understanding as reasons for non-adherence in their patients.
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OBJECTIVES: High risk medication (HRM) use in the elderly is a quality measure 
that contributes to the CMS Star Rating. Various clinical programs to target HRM 
have been described; however, the impact of interventions among the dual eligible 
(DE) Medicare Advantage population is unknown. The objective of this study is to 
compare the impact of a faxed alert intervention directed at HRMs between DE 
and non-DE Medicare Advantage beneficiaries. METHODS: This was a retrospective 
study of pharmacy claims data among Medicare Advantage beneficiaries > 65 years 
of age in 2014. HRMs were defined by industry standard of the American Geriatric 
Society Beers Criteria for Potentially Inappropriate Medication use in Older Adults. 
The HRM Avoidance Program alerts the prescribing provider via fax regarding the 
HRM with recommended alternative(s). Eligible interventions were identified by the 
first HRM fill in the calendar year. Intervention success was defined when a recom-
mended alternative medication was subsequently filled and/or no subsequent fill 
for the same HRM occurred for > 3 months from the index claim date. RESULTS: 
This data represents 926,585 non-DE and 178,840 DE Medicare Advantage benefi-
ciaries. A total of 127,900 pharmacy claims were eligible for the HRM Avoidance 
Program. Of these, 113,627 (89%) were among non-DE and 14,273 (11%) were among 
DE Medicare beneficiaries. The HRM Avoidance Program was successful among 
42% of non-DE compared to 44% of the DE Medicare beneficiaries receiving the 
intervention (p< 0.0001). Significantly higher success rates were observed among 
DE compared to non-DE beneficiaries with the following medication claims: butal-
bital (p= 0.005), carisprodal (p< 0.0001), cyclobenzaprine (p< 0.0001), estrogens 
(p= 0.003), indomethocin (p= 0.001), methocarbamol (p< 0.0001), and promethazine 
(p< 0.0001). CONCLUSIONS: The fax interventions targeting HRM was more success-
ful in the DE than the non-DE Medicare Advantage population. However, further 
research is needed to understand the factors behind the difference in success for 
these populations.
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OBJECTIVES: The Affordable Care Act (ACA) has introduced several major changes 
which can impact product pricing, access and uptake in the United States. The 
objective of this analysis was to review all major new changes due to ACA and 
develop implications for market access for medical products. METHODS: The new 
pricing, access and coverage changes impacting the pharmaceutical and devices 
products were reviewed using the bill for ACA (H. R. 3590), 2011-2013 policy publica-
tions, reports by the Congressional Budget Office and Government Accountability 
Office, and the latest Centers for Medicare & Medicaid Services (CMS) guidelines 
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net searches of relevant websites (such as different health technology assessment 
agencies in Europe). Researchers conducted discussions with payers and biopharma 
experts to identify the perceived differences in pricing negotiations between coun-
tries. RESULTS: There are distinctive differences in the approaches to pricing nego-
tiations between payers in the US and Europe. These lead to determinable patterns 
in the methods that biopharma companies leverage to price their products and in 
the methods that payers use, by either working with the biopharma companies or 
creating reimbursement mechanisms to guide the appropriate utilization of these 
products. European payers have more central negotiating leverage and more for-
malized health technology assessments, which enable them to negotiate and even 
mandate prices and/or develop outcome-based contracts. CONCLUSIONS: Unlike 
European payers, most US payers do not have the support of similar government-
backed organizations for negotiating price, and most cannot optimally leverage 
health technology assessments. This forces US payers to seek more creative ways of 
managing the utilization of products through medical policies, prior authorizations 
and creative reimbursement methods.
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OBJECTIVES: Prices of medicines differ across EU Member States due to factors, 
some of which are beyond responsibilities of companies. These differences include: 
wholesaler or pharmacy margins, sales tax, pack sizes, distribution channels, 
exchange rate fluctuations, and perhaps most importantly, price-setting processes, 
but also national health and pharmaceutical policies and priorities. Current EU 
transfer pricing rules only address process rather than the resulting levels of pric-
ing and reimbursement. Member States compare and reference price with each 
other (so called ‘International Reference Pricing’ or IRP). We aim to demonstrate 
that companies need to employ a range of different mechanisms to mitigate the 
effects of IRP. METHODS: We review how legislation and case law, including that 
relating to parallel trade or grey market, reinforces national rights to set prices. 
Current price constraints and their interpretation are considered. We then consider 
forthcoming proposals and the extent to which they may lead to greater pricing 
consistency. RESULTS: Based on a review of all nine cases that have proceeded to 
the EU courts, the principle of EU member state discretion in terms of price set-
ting seems currently sacrosanct and it is unlikely that the legislators will be able 
to change this position. In order to balance the respective interests of the industry 
and member states, member states should allow differential pricing; restrict IRP to 
economically comparable Member States; exclude from IRP those elements related 
to pharmaceutical regulation and policies, which are country-specific and likely to 
distort price comparisons; and exclude from IRP and free movement provisions, 
those countries under austerity measures. CONCLUSIONS: Currently, manufac-
turers have limited strategies in terms of price corridors and the like; it seems 
therefore, that more pragmatic solutions will need to be considered at an EU level 
and supported by the Courts.
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OBJECTIVES: In the absence of randomized controlled trials (RCTs) for informing 
clinical effectiveness, manufacturers need to rely on alternative methods for the 
generation of clinical evidence for HTA purposes. As the body of evidence based on 
observational study designs grows, there is a need to understand whether and how 
non-randomized evidence can be incorporated into HTAs globally. The aim of this 
study was to collate and compare published HTA guidance on the use and accept-
ance of non-randomized evidence to inform clinical effectiveness. METHODS: 
Guidelines referring to methods for economic evaluation in the UK, Ireland, 
Australia, Canada, and Germany, were searched for information on the use of non-
randomized evidence to demonstrate clinical effectiveness. Technology appraisals 
and reports from evidence review groups (ERGs) (published 2004–2014) in the oncol-
ogy setting, were assessed to identify circumstances in which non-randomized evi-
dence was submitted in HTAs, and to understand how this evidence was considered 
by ERGs. RESULTS: A lack of clear guidance was found regarding when and how 
non-randomized evidence can be used to support HTAs. Although the majority of 
HTAs request that a systematic search for non-RCT data be conducted, few HTAs 
considered non-randomized evidence relevant to clinical effectiveness outcomes. 
Observational data were submitted to HTA bodies in order to: complement and 
extrapolate RCT evidence, test the integrity of evidence synthesis networks, and 
inform long-term safety outcomes. Feedback regarding the appropriateness of 
observational data was minimal or absent in many ERG reports. CONCLUSIONS: 
There is a need for HTA bodies to provide clearly defined guidance regarding the 
use and appropriateness of observational data for HTA purposes. Currently, there 
is no clear consensus on the value that non-randomized evidence can offer from 
a HTA perspective.
PHP114
A sUrvey of isPor Attendee views on tHe Use of icer And AccePtABle 
icer tHresHolds
Kaura S.1, Seetasith A.2, Ramesh V.2, Nanavaty M.2, Proach J.2, Khan Z.M.1
1Celgene Corporation, Summit, NJ, USA, 2Market Access Solutions LLC, Raritan, NJ, USA
OBJECTIVES: The study aims to assess the perspectives of different healthcare 
stakeholders on the current incremental cost-effectiveness ratio (ICER) thresh-
olds and understand if these are still considered appropriate for their intended 
model was employed to estimate factors associated with where a new drug was 
reimbursed by NHI and its reimbursement lag. RESULTS: We found that for new 
drugs in Taiwan, the median of marketing lag was 26.84 month while the median of 
reimbursement lag was 11.83 months. About 84% of new drugs were reimbursed by 
NHI. The reimbursement decision were mainly associated with the characteristics 
of medications, including their types of therapy and innovation categories. The 
price-related factors were significantly related with the reimbursement lag but not 
whether medications were reimbursed. CONCLUSIONS: By examining the barriers 
at different stages from drug approval to NHI reimbursed, this study provided dif-
ferent perspectives for health policy makers to examine issues on drug approval, 
health care resource allocation, and quality of medical care.
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OBJECTIVES: In Germany, the reimbursement and pricing of innovative in-patient 
drugs and devices is managed through the NUB application process. These applica-
tions are submitted by the hospital stakeholder and are approved or rejected by the 
Institute for the Hospital Remuneration System (InEK). The objective of this research 
was to assess the NUB trends in Germany in 2012-2014. METHODS: We developed 
a database of NUB approvals and rejections based on the Institute for the Hospital 
Remuneration System’s (InEK )’s reports. All information was extracted into Excel 
format. The following data was extracted: product name, indication, year of submis-
sion, number of NUB applications submitted, status score, type of evidence available 
and lack of evidence for NUB rejection. Additionally, the number of re-applications 
and re-rejections were also analyzed. RESULTS: In 2013 and 2014, a total of 21264 
and 25634 NUB applications were submitted for 612 and 613 medical products, 
respectively. Of these applications in 2013 and 2014, 10% and 16% were approved 
for NUB (as Status 1) and 82% and 75% were rejected (as Status 2), respectively. In 
2014, the median number of hospital applications for NUBs with Status 1 and Status 
2 were 37 and 3, demonstrating the importance of hospital participation for seek-
ing NUB approval. Among approved NUBs, 37% of the applications were for drugs 
and 63% were for devices. Interestingly, the median NUB hospital applications for 
approved drugs was 192, while for devices, the median was 9 applications. In 2014, 
447 NUB applications for products were re-submitted, of which 5 were approved and 
the remaining were re-rejected. The evidence requirements analysis suggests the 
need for hospital focused economic data. CONCLUSIONS: The NUB process plays 
a critical role in market access for in-patient drugs and devices. For approval, two 
key components are: hospital focused economic evidence and provider stakeholder 
involvement.
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OBJECTIVES: International Reference Pricing (IRP) is a key cost-containment tool 
for health care payers across the world. IRP may apply either fixed or flexible rules 
to calculate the price of branded drugs. Typically there is no negotiation between 
manufacturers and the IPR body. In the context of the German AMNOG price negotia-
tions and the role of Germany as a key referenced country, there is dearth of real-life 
evidence on the international impact of the AMNOG law. METHODS: The publicly 
available IRP rules were screened and evaluated systematically. Based on these find-
ings an IRP model was developed to simulate scenarios of price agreements for a 
new drug between the German Head Association of the Statutory Health Insurance 
Companies and the manufacturer. The impact of the price agreement on other coun-
tries was analyzed based on the existing IRP rules. RESULTS: We simulated a hypo-
thetical price dataset for a branded drug X with all prices set at 100 euro to limit the 
impact to Germany only. A 25% price drop in Germany would lead to a range of 32.5% 
reduction in Egypt and almost 1% in Austria. The largest impact in Europe would 
be in France, Romania, Russia, Slovenia, Luxembourg (-25%), followed by Norway 
and Greece (-8.33%), the Netherlands (-6.25%), Switzerland, Ireland and Denmark. A 
price drop of 50% in Germany would double the impact with the exception of Egypt 
(-55%). However, a limited impact was observed if the price increase in Germany was 
25%.That would lead to 6.25% increase in the Netherlands, 4.17% in Switzerland, 
2.78% in Ireland and Denmark, and about 1% increase in Austria. CONCLUSIONS: 
Price negotiations in Germany could potentially impact the price of new branded 
therapies in other countries. This could ultimately lead to a price-downward spiral 
with a negative impact on innovation and drug development in Europe.
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OBJECTIVES: In recent years, the pharmaceutical industry has received approval 
in the US and Europe for several products that are unique, meet previously unmet 
needs, and yield important reductions in mortality and morbidity. Frequently, these 
products are orphan and even ultra-orphan drugs targeted at very small patient 
populations. It is common for these products to be priced up to $500,000 per annum. 
This research reviewed the pricing of these unique products (including trends) and 
explored alternative funding strategies that have been negotiated (e.g. outcome 
contracts) and/or are being proposed (e.g. reimbursement methods) by payers to 
manage their budgets. METHODS: We conducted research on the publicly available 
data on unique biopharma products and their pricing through literature and inter-
